Publications by authors named "Anasuya Vishvanath"

Claim this Profile
H
High-throughput screening identifies Ceefourin 1 and Ceefourin 2 as highly selective inhibitors of multidrug resistance protein 4 (MRP4).
Leanna Cheung, Claudia L Flemming, Fujiko Watt, Nanako Masada, Denise M T Yu, Anasuya Vishvanath

Biochem Pharmacol· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infantile haemangioma expresses embryonic stem cell markers.
Tinte Itinteang, Swee T Tan, Helen D Brasch, Ryan Steel, Heather A Best, Anasuya Vishvanath

J Clin Pathol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL).
Anasuya Vishvanath, Tinte Itinteang, Swee T Tan, Darren J Day

Histopathology· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesenchymal stem cells in infantile haemangioma.
Tinte Itinteang, Anasuya Vishvanath, Darren J Day, Swee T Tan

J Clin Pathol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ethnic differences in nicotine metabolic rate among New Zealanders.
Rod Lea, Neal Benowitz, Michael Green, Jeff Fowles, Anasuya Vishvanath

N Z Med J· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
Purva Bali, Prince George, Pamela Cohen, Jianguo Tao, Fei Guo, Anasuya Vishvanath

Clin Cancer Res· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3.
Prince George, Purva Bali, Pamela Cohen, Jianguo Tao, Fei Guo, Anasuya Vishvanath

Cancer Res· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis